Thromboembolic Risk of Thrombopoietin Receptor Agonists for Adult Primary Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis Integrating Randomized Controlled Trials and Prospective Evidence
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025-11 · 45 (11) · 764-773
DOI: 10.1002/phar.70075 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 12.11.2025. Verfasst von Meng-Fei Dai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. Hauptthemen laut MEDLINE: Receptors, Thrombopoietin, Thromboembolism, Purpura, Thrombocytopenic, Idiopathic, Thrombopoietin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: the Medical Health Science and Technology Project of Zhejiang Province (2023KY606, 2023KY608, 2025KY723), HER2 targets research fund of Chinese anti-cancer association (CETSDSSCORP239-061)., Shining Across China-Medicinal Research Fund (Z04JKM2023E040).
Abstract (Originalsprache)
Background
Although randomized controlled trials (RCTs) have established evidence regarding thromboembolic risks of thrombopoietin receptor agonists (TPO‐RAs) in immune thrombocytopenia (ITP) during short‐term follow‐up, the long‐term risks remain uncertain. This meta‐analysis integrates data from prospective studies and RCTs to provide a comprehensive evaluation of thromboembolic risks associated with TPO‐RA therapy.
Methods
PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to January 23, 2025 for RCTs and prospective studies reporting thromboembolic events in patients treated with TPO‐RAs. The primary outcome was the risk of any thromboembolism. Subgroup analyses separately assessed the incidence of venous and arterial thrombosis. Short‐term (≤ 6 months) evidence was derived from RCTs, while long‐term (6–12 months and > 12 months) evidence was supplemented by prospective studies. Data from RCTs were analyzed using the Peto odds ratio (OR) with 95% confidence intervals (CIs), and data from prospective studies were pooled to calculate the incidence of thromboembolic events.
Results
The analysis included 12 RCTs (involving 1530 patients) and 11 prospective studies (involving 1820 patients). TPO‐RAs significantly increased thromboembolic risk compared to placebo in the short‐term (0.72% vs. 0.23%, Peto OR = 3.25, 95% CI = 1.11–9.51, p = 0.03). Pooled results from prospective studies demonstrated thromboembolism incidence of 3.84% at 6 to 12 months and 5.59% beyond 12 months of treatment with TPO‐RAs. The reported incidence of arterial thrombosis increased from 0.14% (≤ 6 months) to 1.51% (6–12 months), and further to 4.2% (> 12 months). Whereas the reported incidence of venous thrombosis increased from 0.18% (≤ 6 months) to 2.50% (6–12 months), and plateaued at 2.55% beyond 12 months.
Conclusion
This analysis demonstrates that TPO‐RAs therapy increases the risk of thromboembolism, with the risk of arterial events becoming particularly pronounced during long‐term use. These findings highlight the need for individualized risk assessment and vigilant monitoring in patients receiving TPO‐RAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
- Department of Pharmacy, Zhejiang Hospital, Hangzhou, China.
- Department of Pharmacy, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, China.
ORCID-Profile: Meng-Fei Dai, Gao-Wei Chong, Wen-Xiu Xin, Hai-Ying Ding
Förderung
- the Medical Health Science and Technology Project of Zhejiang Province (2023KY606, 2023KY608, 2025KY723)
- HER2 targets research fund of Chinese anti-cancer association (CETSDSSCORP239-061).
- Shining Across China-Medicinal Research Fund (Z04JKM2023E040)
Zitieren
APA
Dai, M. F., Chong, G. W., Xin, W. X., Kong, S. S., Zhu, J. F., Zhong, L. K., Xu, G. Q., Jin, X. Y., He, C. N., Wang, T. T., Mi, X. F., Luo, L., Song, Z. J., Ding, H. Y., & Fang, L. (2025). Thromboembolic Risk of Thrombopoietin Receptor Agonists for Adult Primary Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis Integrating Randomized Controlled Trials and Prospective Evidence. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 45(11), 764-773. https://doi.org/10.1002/phar.70075
Vancouver
Dai MF, Chong GW, Xin WX, Kong SS, Zhu JF, Zhong LK, et al. Thromboembolic Risk of Thrombopoietin Receptor Agonists for Adult Primary Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis Integrating Randomized Controlled Trials and Prospective Evidence. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025;45(11):764-773. doi:10.1002/phar.70075
BibTeX
@article{Dai2025,
author = {Dai, Meng-Fei and Chong, Gao-Wei and Xin, Wen-Xiu and Kong, Si-Si and Zhu, Jun-Feng and Zhong, Li-Ke and Xu, Gao-Qi and Jin, Xiang-Yu and He, Chao-Neng and Wang, Ting-Ting and Mi, Xiu-Fang and Luo, Liping and Song, Zhu-Jin and Ding, Hai-Ying and Fang, Luo},
title = {Thromboembolic Risk of Thrombopoietin Receptor Agonists for Adult Primary Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis Integrating Randomized Controlled Trials and Prospective Evidence},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2025},
volume = {45},
number = {11},
pages = {764--773},
doi = {10.1002/phar.70075}
}
EUVIMED